HDN Investment Joint Stock Company and Relisys Medical Devices Limited are pleased to announce the successful participation in Vietnam Valves 2026, held from September 25 to 26, 2026, at the New World Saigon Hotel in Ho Chi Minh City, Vietnam.
Last weekend, HDN Investment Joint Stock Company, in collaboration with RELISYS, participated in the Vietnam Valves 2026 Conference, a specialized scientific forum dedicated to TAVI and transcatheter heart valve interventions in Vietnam. At the event, HDN and RELISYS introduced their latest advancements and received enthusiastic feedback from the medical community and fellow healthcare professionals.
Representatives from HDN and RELISYS, alongside chairpersons and speakers: Dr. Rajaram Anantharaman (Kauvery Hospital, India) and Dr. Marco Solinas (Fondazione Toscana Gabriele Monasterio Hospital, Italy).
From September 25–26, the Vietnam Valves 2026 Scientific Conference concluded successfully in Ho Chi Minh City. This prestigious international forum brought together over 15 international chairpersons and speakers (from the UK, USA, Spain, Italy, India, Singapore, South Korea, Taiwan, Hungary, etc.) alongside 83 leading domestic experts in cardiology, cardiovascular surgery, interventional cardiology, and diagnostic imaging.
At this year's conference, HDN Investment Joint Stock Company partnered with RELISYS to showcase advanced transcatheter heart valve technologies, delivering breakthrough solutions for physicians operating under the "Heart Team" model in Vietnam.
Promoting the Heart Team model for optimal patient outcomes
The Opening Ceremony of the Vietnam Valves 2026 Conference at the New World Saigon Hotel, Ho Chi Minh City.
In recent years, Valvular heart disease remains a critical focus in clinical cardiology. Powerful advancements in diagnostic imaging, medical management, and structural heart interventions, particularly Transcatheter Aortic Valve Implantation (TAVI), are unlocking new opportunities to improve patient prognoses and quality of life. However, these rapid developments also demand higher standards of multidisciplinary coordination, continuous knowledge updates, and standardized clinical practices.
Aiming to optimize treatment outcomes and prioritize patient benefits, the Vietnam Valves 2026 Scientific Conference centered on updating the latest global clinical evidence and trends, discussing advanced structural heart therapies in depth, and enhancing the clinical efficiency of the Heart Team model.
The speakers interested in Vienna Aortic Valve and TricValve Therapy.
During the second day of the conference, the presentation by Dr. Rajaram Anantharaman sparked lively discussions among experts as he introduced two groundbreaking medical solutions.
1. Vienna Aortic Valve: The World's Only Pre-loaded Dry Tissue Technology
Transcatheter Aortic Valve Implantation (TAVI) is saving the lives of countless patients. With the Vienna Aortic Valve from RELISYS, experts explored the exceptional potential of dry tissue technology integrated into a highly convenient, pre-loaded TAVI system. The Vienna Valve stands out with its "ready-to-use" system, which minimizes preparation time in the operating room, eliminates complex valve rinsing procedures, and significantly enhances safety and precision during interventions.
Dr. Rajaram Anantharaman, Director of the Center for Advanced Heart Failure, Cardiomyopathy, Mechanical Circulatory Support, and Heart Transplantation at Kauvery Hospital (India), delivering his presentation: "The World's Only Pre-loaded Dry Tissue TAVI Valve".
2. TricValve Therapy: Transcatheter Caval Valve System
Addressing tricuspid regurgitation, which is a major hurdle in cardiovascular treatment, the session provided updates on cutting-edge transcatheter approaches. Among them, the TricValve therapy was highly rated as a breakthrough solution that significantly improves patient prognosis and quality of life without the high risks associated with open-heart surgery.
Dr. Rajaram Anantharaman presented on the transcatheter caval valve system, highlighting the TricValve therapy. The immense potential of the Vienna and TricValve systems from Relisys captured strong interest from international chairpersons.
Below are additional highlights of HDN and RELISYS at the event:
HDN Investment Joint Stock Company extends its heartfelt gratitude to Dr. Rajaram Anantharaman for his invaluable clinical insights into the TricValve platform and the Vienna Aortic Valve technology by RELISYS. We would also like to express our deepest appreciation to the Board of Chairpersons, the speakers, and all distinguished delegates and medical professionals who visited the RELISYS and HDN exhibition booth.
The interest and constructive feedback of the delegates serve as a powerful motivation for HDN to continue bridging the gap, bringing the world's most advanced medical technologies to serve the national healthcare sector.
On October 9, a specialized seminar on the technology and applications of advanced 3T magnetic resonance imaging (MRI) in neurovascular and musculoskeletal fields was held in Nghe An. The program was a scientific event jointly organized by GE HealthCare and Minh An General Hospital.
Last weekend, HDN Investment Joint Stock Company (HDN), in collaboration with GE HealthCare and the Hope Foundation (VnExpress newspaper), successfully organized the "Miracle Fair - Synchronized Hearts" program for hundreds of pediatric patients in Nghe An, Vietnam.
On August 7, Trans-Asia General Hospital System officially signed an agreement with HDN Investment Joint Stock Company (HDN) to invest in and procure diagnostic imaging systems from GE HealthCare.
On October 9, a specialized seminar on the technology and applications of advanced 3T magnetic resonance imaging (MRI) in neurovascular and musculoskeletal fields was held in Nghe An. The program was a scientific event jointly organized by GE HealthCare and Minh An General Hospital.
Last weekend, HDN Investment Joint Stock Company (HDN), in collaboration with GE HealthCare and the Hope Foundation (VnExpress newspaper), successfully organized the "Miracle Fair - Synchronized Hearts" program for hundreds of pediatric patients in Nghe An, Vietnam.
HDN Investment Joint Stock Company and Relisys Medical Devices Limited are pleased to announce the successful participation in Vietnam Valves 2026, held from September 25 to 26, 2026, at the New World Saigon Hotel in Ho Chi Minh City, Vietnam.
On August 7, Trans-Asia General Hospital System officially signed an agreement with HDN Investment Joint Stock Company (HDN) to invest in and procure diagnostic imaging systems from GE HealthCare.
Last week, HDN Investment Joint Stock Company, together with GE HealthCare, attended the scientific conference celebrating the 45th anniversary of Vietnam – Cuba Dong Hoi Friendship Hospital.
From 24–26 July, Crowne Plaza Da Nang welcomed leading respiratory physicians and interventional pulmonology specialists from Vietnam and abroad for the Vietnam Respiratory Society Annual Scientific Congress (VNRS 2026).
On the evening of 24 July, HDN Investment Joint Stock Company, in collaboration with ForTsing Medical (Hong Kong), organized a pre-congress Dinner Symposium entitled "A New Era of AI Technology in Interventional Pulmonology" at Crowne Plaza Da Nang, ahead of the Vietnam Respiratory Society Annual Scientific Congress (VNRS 2026).
Over the past two decades, HDN has steadily strengthened its position by building on core values centered around product quality, professional service, and the trust of customers and strategic partners.
As a strategic distribution partner of GE HealthCare in Vietnam, HDN’s participation reaffirmed the company’s strong market development capabilities, implementation expertise, and long-term commitment to accompanying GE HealthCare in delivering advanced medical technologies to healthcare facilities across Vietnam.
.png)
.png)
.png)
.png)
.png)
.jpg)